Derrick Williamson, DO
Family Medicine · Southfield, MINPI 1215922059
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,726 of the $7,437 with a category attached, or 63.5%. 11 manufacturers reported payments, led by Modernatx, Inc. at 51.8% of the total. Reporting peaked in 2024 at $2,851 and has fallen 86.1% since, to $396 in 2025. Among family medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 58 payments — averaging $128.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$4K
- AstraZeneca$3K
- Takeda Pharmaceuticals U.S.A., Inc.$226
- AbbVie$150
- Novo Nordisk$125
- Boehringer Ingelheim$24
- plus $90 from 5 others
Across 662 payments — averaging $14,917 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$7.8M
- Pfizer$622K
- Eli Lilly$545K
- BD$397K
- Cue Health Inc.$336K
- Sanofi$96K
- plus $80K from 4 others
What the payments were for
- Travel & lodging$2,71136%
- Food & beverage$4,72664%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 20 | $3,851 |
| AstraZeneca | 27 | $2,971 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $226 |
| AbbVie | 2 | $150 |
| Novo Nordisk | 1 | $125 |
| Boehringer Ingelheim | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Pfizer | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,437 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 14 | $21,153 |
| FarxigaDapagliflozin Propanediol | 11 | $16,433 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 34 | $2,249 |
| Atorvastatin Calcium | 31 | $501 |
| Olmesartan Medoxomil | 13 | $407 |
| Rosuvastatin Calcium | 17 | $207 |
| Metoprolol Succinate | 15 | $175 |
| Allopurinol | 16 | $164 |
| Levothyroxine Sodium | 19 | $144 |
| Metformin Hcl | 11 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $125 | $21,15314 claims |
| AstraZenecaFarxiga | $2,971 | $16,43311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Southfield
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
- Timothy IzzoGrand Ledge$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.